Pulmonary Fibrosis News Home | Pulmonary Fibrosis News
WEBPhase 2b trial tests AP01, inhaled pirfenidone, in progressive PF. Avalyn Pharma has started a Phase 2b clinical trial testing the safety and efficacy of AP01, its investigational inhaled formulation of pirfenidone, in adults with progressive pulmonary fibrosis (PF).
Aileron Therapeutics Completes Enrollment in Cohort 2 of the …
WEB14 hours ago · IPF is a chronic lung disease characterized by progressive tissue scarring that prevents proper lung function. It is a progressive, fatal, age-associated lung disease affecting approximately ...
New prototype therapy may repair IPF lung scarring by …
WEBApr 26, 2024 · Researchers have developed an inhalable prototype medicine that may be able to repair lung scarring caused by idiopathic pulmonary fibrosis (IPF) by stimulating the growth of stem cells directly in the lungs, a study reports.
Insilico Medicine reports positive Phase IIa | EurekAlert!
WEB6 days ago · Insilico Medicine reports positive Phase IIa results for ISM001-055, a novel first-in-class drug treatment for idiopathic pulmonary fibrosis (IPF) designed using generative AI. Positive results ...
BMS-986278 declared breakthrough therapy for progressive PF
WEBOct 27, 2023 · The FDA’s decision to grant breakthrough therapy designation to BMS-986278 was based on results from a global Phase 2 clinical trial (NCT04308681) assessing the safety and efficacy of BMS-986278 in 278 people with …
Experimental anticancer drug shows promise as treatment for …
WEBAug 23, 2022 · An experimental anticancer drug called saracatinib shows promise as a treatment for Idiopathic Pulmonary Fibrosis (IPF), a chronic and often fatal condition that causes scarring or fibrosis of the lungs and makes breathing difficult.
Newly Designed Molecule Is Promising Potential Therapy for …
WEBOct 28, 2022 · A team led by Kaminski used a newly designed molecule, called MRG-229, with potential therapeutic implications for IPF. The study is one of the first to use a microRNA mimic as a viable therapeutic in the lungs. The group published its findings October 17 in eBioMedicine.
FDA Grants Breakthrough Therapy Designation for IPF | Press
WEBFeb 24, 2022 · Ridgefield, Conn. and Ingelheim, Germany, February 24, 2022 – Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to its novel investigational therapy, BI 1015550, for the treatment of idiopathic pulmonary fibrosis (IPF).
Researchers identify new molecular target for idiopathic …
WEBMar 10, 2021 · Researchers have identified a new molecular target that could lead to new treatments for idiopathic pulmonary fibrosis (IPF), a deadly lung disease. IPF is characterized by severe scarring of the lungs, a condition called fibrosis, which makes it progressively difficult to breathe.
First patient enrolled in FIBRONEER™-IPF Phase III trial
WEBRidgefield, Conn. and Ingelheim, Germany, October 26, 2022 – Boehringer Ingelheim today announced that the first U.S. patient has enrolled in FIBRONEER ™ -IPF, a global Phase III trial evaluating BI 1015550, an investigational phosphodiesterase 4B (PDE4B) inhibitor, in people living with idiopathic pulmonary fibrosis (IPF).
Skip to content